Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). - Burchert A; Nicolini FE; le Coutre P; Saussele S; Hochhaus A; Tuere E; Metzelder SK; Pauck K; Garn H; Raifer H; Huber M; Gattermann N; et al. (Leukemia, 2026)